One suggested limitation is that alterations of neuroplasticity in certain brain regions produce a pro-depressive effect. Some studies suggest that neuroplasticity in the mesolimbic dopamine circuit can produce effects that are opposite to the antidepressant effects observed in the hippocampus. Although circumstantial, there is evidence that neuroplasticity in the amygdala may work contrary to antidepressant effects. There is a concern that novel therapeutic strategies aimed at enhancement of neuroplasticity may have unintended pro-depressant effects through their impact on the nucleus accumbens or other structures outside the hippocampal
One suggested limitation is that alterations of neuroplasticity in certain brain regions produce a pro-depressive effect. Some studies suggest that neuroplasticity in the mesolimbic dopamine circuit can produce effects that are opposite to the antidepressant effects observed in the hippocampus. Although circumstantial, there is evidence that neuroplasticity in the amygdala may work contrary to antidepressant effects. There is a concern that novel therapeutic strategies aimed at enhancement of neuroplasticity may have unintended pro-depressant effects through their impact on the nucleus accumbens or other structures outside the hippocampal